Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSabine GaerditzMMMichał MielnikMSM Hasib Sidiqi

Discussion

Loading...

Member takes

Overview

Phase 1b trial demonstrates tolerability and promising anti-tumor activity of etentamig combined with pomalidomide and dexamethasone in relapsed multiple myeloma.

Key Points

  • This study evaluates the tolerability and efficacy of etentamig combined with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
  • Multi-arm open-label, multi-center Phase 1b dose-escalation study in 7 countries.
  • Patients with relapsed or refractory multiple myeloma received etentamig with pomalidomide and dexamethasone.
  • Investigators assessed responses using International Myeloma Working Group 2016 criteria.
  • Combination therapy was administered to 85 patients, with a median follow-up of 18 months.
  • Treatment showed an overall response rate of 81% and a very good partial response rate of 72%.
  • Median progression-free survival has not been reached, indicating prolonged disease control.

Cite This Study

Gaerditz et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfdchttps://doi.org/10.1182/blood-2025-247
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses2025
  2. 2Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis2025 · 3 citations
  3. 3Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data2025
  4. 4Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma2025
  5. 5Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 12025 · 1 citations